A detailed history of Wells Fargo & Company transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 99,298 shares of AKBA stock, worth $182,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,298
Previous 96,099 3.33%
Holding current value
$182,708
Previous $98,000 33.67%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.94 - $1.55 $3,007 - $4,958
3,199 Added 3.33%
99,298 $131,000
Q2 2024

Aug 13, 2024

BUY
$0.86 - $1.63 $75,729 - $143,532
88,057 Added 1094.96%
96,099 $98,000
Q1 2024

May 10, 2024

SELL
$1.27 - $2.24 $3,878 - $6,840
-3,054 Reduced 27.52%
8,042 $14,000
Q4 2023

Feb 09, 2024

BUY
$0.8 - $1.28 $66 - $106
83 Added 0.75%
11,096 $13,000
Q3 2023

Nov 13, 2023

SELL
$0.87 - $1.84 $102 - $217
-118 Reduced 1.06%
11,013 $12,000
Q2 2023

Aug 15, 2023

SELL
$0.51 - $1.43 $577 - $1,620
-1,133 Reduced 9.24%
11,131 $10,000
Q1 2023

May 12, 2023

SELL
$0.56 - $1.15 $680 - $1,397
-1,215 Reduced 9.01%
12,264 $6,000
Q4 2022

Feb 13, 2023

SELL
$0.25 - $0.58 $83 - $194
-335 Reduced 2.43%
13,479 $7,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $0.46 $342 - $525
-1,142 Reduced 7.64%
13,814 $4,000
Q2 2022

Aug 12, 2022

SELL
$0.32 - $0.67 $89,816 - $188,053
-280,677 Reduced 94.94%
14,956 $4,000
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $37,670 - $153,297
-52,320 Reduced 15.04%
295,633 $212,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $456,843 - $675,157
202,143 Added 138.63%
347,953 $787,000
Q3 2021

Nov 15, 2021

BUY
$2.35 - $3.88 $296,473 - $489,496
126,159 Added 642.0%
145,810 $421,000
Q2 2021

Aug 16, 2021

SELL
$2.83 - $4.2 $251,145 - $372,724
-88,744 Reduced 81.87%
19,651 $75,000
Q1 2021

May 13, 2021

SELL
$2.92 - $5.06 $444,748 - $770,693
-152,311 Reduced 58.42%
108,395 $367,000
Q4 2020

Feb 09, 2021

SELL
$2.22 - $3.78 $113,628 - $193,475
-51,184 Reduced 16.41%
260,706 $730,000
Q3 2020

Nov 05, 2020

BUY
$2.39 - $13.08 $13,305 - $72,816
5,567 Added 1.82%
311,890 $782,000
Q2 2020

Aug 13, 2020

BUY
$6.67 - $13.58 $426,679 - $868,712
63,970 Added 26.4%
306,323 $4.16 Million
Q1 2020

May 14, 2020

BUY
$4.1 - $10.24 $993,647 - $2.48 Million
242,353 New
242,353 $1.84 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.